Published in AIDS Weekly, June 19th, 2006
Study 1: Clinical markers and tolerability are similar among HIV-infected patients given protease inhibitor or non-nucleoside reverse-transcriptase inhibitor-based regimens during early infection.
"Treatment of acute human immunodeficiency virus type 1 (HIV-1) infection may have unique immunologic, virological, and clinical benefits. However, the timing of treatment, optimal starting regimens, and expected response to therapy have not been defined," scientists in the United States report.
According to S. Kassutto and colleagues at Massachusetts...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.